- ICH GCP
- 미국 임상 시험 레지스트리
- 임상시험 NCT04554914
Epstein-barr 바이러스 관련 질병을 가진 참가자에서 Tabelecleucel을 평가하기 위한 연구
엡스타인-바 바이러스 관련 질병을 앓는 피험자에서 타베클레류셀의 효능 및 안전성을 평가하기 위한 공개 라벨, 단일군, 다중 코호트, 2상 연구
The purpose of this study is to assess the efficacy and safety of tabelecleucel in participants with EBV-associated diseases.
연구 개요
상태
정황
개입 / 치료
상세 설명
This is a multicenter, multicohort, open-label, single-arm, Phase 2 study to assess the efficacy and safety of tabelecleucel for the treatment of EBV-associated diseases. Participants will be enrolled in one of the following cohorts:
- EBV+ lymphoproliferative disease (LPD) in the setting of primary immunodeficiency (PID) (EBV+ PID LPD) that is relapsed and/or refractory (R/R) or newly diagnosed where standard first-line therapy is inappropriate
- EBV+ LPD in the setting of acquired (non-congenital) immunodeficiency (AID) (EBV+ AID LPD) that is R/R or newly diagnosed where standard first-line therapy is inappropriate [cohort closed for enrollment after completion of stage1]
- EBV+ post-transplant lymphoproliferative disease (PTLD) involving the central nervous system (CNS) (EBV+ CNS PTLD) that is R/R or newly diagnosed where standard first-line therapy is inappropriate
- EBV+ PTLD where standard first-line therapy (rituximab or chemotherapy) is inappropriate, including cluster of differentiation antigen 20 (CD20)-negative disease
- EBV+ sarcomas, including leiomyosarcoma (LMS), or smooth muscle tumors that is rapidly progressive where standard first-line therapy is inappropriate
Tabelecleucel will be administered in cycles lasting for 35 days. During each cycle, participants will receive tabelecleucel at a dose of 2 x 10^6 cells/kg intravenously (IV) weekly for 3 weeks, followed by observation through Day 35. Treatment will continue until maximal response, disease progression, unacceptable toxicity, or initiation of nonprotocol therapy for the underlying disease. For EBV+ sarcoma cohort, treatment will continue until disease progression, unacceptable toxicity, two consecutive complete responses (CRs), or up to 12 months from the first dose. Participants who fail to respond to initial tabelecleucel treatment may continue tabelecleucel with a different human leukocyte antigen (HLA) restriction (termed a Restriction Switch), if available; administration of tabelecleucel with up to four different HLA restrictions is allowed for any participant.
After treatment is completed or discontinued, participants will complete a safety follow-up visit at 30 days after the last dose and then will enter a quarterly follow-up period. Participants without documented disease progression will be assessed every 3 months after the safety follow-up visit for continued evaluation of disease response until the end of study (EOS) visit at which occurs at 12 (± 1) months after Cycle 1 Day 1 for adults, and 24 (± 1) months after Cycle 1 Day 1 for pediatric participants. Participants with disease progression any time prior to the EOS visit will continue to be followed every 3 months for survival status until the EOS visit.
An adaptive 2-stage design will be used for each relevant cohort in this study. For each cohort, 8 evaluable participants will be enrolled in Stage 1. The decision to move to Stage 2 enrollment will be based on an interim analysis of the first 8 evaluable participants in the cohort using investigator's assessment (per defined radiologic, clinical, and/or laboratory response criteria) who receive tabelecleucel and have at least 1 valid postbaseline disease response assessment. The number of participants enrolled in Stage 2 for each cohort will depend on the number of observed responders in Stage 1. Sponsor may decide not to move forward to Stage 2 in any cohort even if the criteria to move forward for that cohort are met. The decision not to move forward may also be based on data from one or other cohorts.
연구 유형
등록 (추정된)
단계
- 2 단계
연락처 및 위치
연구 장소
-
-
California
-
Los Angeles, California, 미국, 90095
- University of California Los Angeles (UCLA) (Adults and Pediatrics)
-
Orange, California, 미국, 92868
- Children's Hospital of Orange County (Pediatrics [up to 25 years old])
-
Palo Alto, California, 미국, 94304
- Lucile Packard Children's Hospital Stanford (Pediatrics only)
-
Sacramento, California, 미국, 95817
- University of California Davis Comprehensive Cancer Center (Adults and Pediatrics)
-
-
Florida
-
Miami, Florida, 미국, 33136
- Sylvester Comprehensive Cancer Center/ University of Miami
-
Tampa, Florida, 미국, 33612
- Moffit Cancer Center (Adults only)
-
-
Georgia
-
Atlanta, Georgia, 미국, 30322
- Children's Healthcare of Atlanta (Pediatrics only [up to 25 years old])
-
Atlanta, Georgia, 미국, 30322
- Emory University/Winship Cancer Institute (Adults [>= 16 years])
-
-
Illinois
-
Chicago, Illinois, 미국, 60611
- Ann & Robert H. Lurie Children's Hospital of Chicago (Pediatrics only)
-
-
Maryland
-
Baltimore, Maryland, 미국, 21201
- University of Maryland Medical Center (Adults only)
-
-
Massachusetts
-
Boston, Massachusetts, 미국, 02215
- Dana Farber Cancer Institute (DFCI) (Adults and Pediatrics)
-
-
Michigan
-
Ann Arbor, Michigan, 미국, 48109
- University of Michigan Rogel Cancer Center (Adults and Pediatrics)
-
-
Minnesota
-
Minneapolis, Minnesota, 미국, 55455
- University of Minnesota (Adults only)
-
-
Missouri
-
St Louis, Missouri, 미국, 63108
- Washington University in St. Louis (Adults only)
-
-
New York
-
New York, New York, 미국, 10032
- Columbia University Irving Medical Center (Adults only)
-
New York, New York, 미국, 10065
- Memorial Sloan-Kettering Cancer Center (Adults and Pediatrics)
-
The Bronx, New York, 미국, 10467
- The Children's Hospital at Montefiore (Adults and Pediatrics)
-
-
Ohio
-
Cleveland, Ohio, 미국, 44195
- Cleveland Clinic Taussig Cancer Center (Adults and Pediatrics)
-
Columbus, Ohio, 미국, 43210
- The Ohio State University - The James Cancer Hospital and Solove Research Institute (Adults only)
-
-
Oregon
-
Portland, Oregon, 미국, 97239
- Oregon Health and Science University (Adults and Pediatrics)
-
-
South Carolina
-
Charleston, South Carolina, 미국, 29425
- Medical University of South Carolina (Adults and Pediatrics)
-
-
Texas
-
Dallas, Texas, 미국, 75390
- University of Texas Southwestern Medical Center (Pediatrics only)
-
Houston, Texas, 미국, 77030
- MD Anderson (Adults and Pediatrics)
-
-
-
-
Brussles
-
Brussels, Brussles, 벨기에, 1020
- Hôpital Universitaire des Enfants Reine Fabiola (Pediatrics only)
-
-
West-Vlaanderen
-
Bruges, West-Vlaanderen, 벨기에, 8000
- Algemeen Ziekenhuis Sint-Jan Brugge-Oostende - Campus Sint-Jan (Adults only)
-
Roeselare, West-Vlaanderen, 벨기에, 8800
- Algemeen Ziekenhuis Delta - Campus Rumbeke (Adults only)
-
-
-
-
Barcelona
-
Barcelona, Barcelona, 스페인, 08035
- Hospital Universitari Vall d'Hebrón (Adults and Pediatrics)
-
-
Madrid
-
Madrid, Madrid, 스페인, 28034
- Hospital Universitario Ramón y Cajal (Adults only)
-
-
Sevilla
-
Seville, Sevilla, 스페인, 41013
- Hospital Universitario Virgen del Rocio (Adults and Pediatrics)
-
-
-
-
England
-
Birmingham, England, 영국, B15 2TH
- University Hospital Birmingham NHS Foundation Trust (Adults only)
-
London, England, 영국, WC1N 3JH
- Great Ormond Street Hospital (Pediatrics only)
-
-
-
-
State of Salzburg
-
Salzburg, State of Salzburg, 오스트리아, 5020
- Uniklinikum Salzburg Landeskrankenhaus (Adults only)
-
-
State of Vienna
-
Vienna, State of Vienna, 오스트리아, 1090
- Medizinische Universität Wien (Adults only)
-
-
Styria
-
Graz, Styria, 오스트리아, 8036
- Medizinische Universität Graz (Adults only)
-
-
-
-
Pisa
-
Pisa, Pisa, 이탈리아, 56126
- Azienda Ospedaliero-Universitaria Pisana (Adults only)
-
-
Roma
-
Roma, Roma, 이탈리아, 00165
- Ospedale Pediatrico Bambino Gesù (Adults and Pediatrics)
-
-
Torino
-
Torino, Torino, 이탈리아, 10126
- Ospedale Infantile Regina Margherita (Pediatrics only)
-
-
-
-
-
Paris, 프랑스, 75013
- Hôpital Universitaire Pitié Salpêtrière (Adults only)
-
-
Montpellier
-
Montpellier, Montpellier, 프랑스, 34295
- Hôpital Saint-Eloi (Adults and Pediatrics)
-
-
Paris
-
Paris, Paris, 프랑스, 75015
- Hôpital Necker-Enfants Malades (Adults and Pediatrics)
-
-
참여기준
자격 기준
공부할 수 있는 나이
- 어린이
- 성인
- 고령자
건강한 자원 봉사자를 받아들입니다
연구 대상 성별
설명
Inclusion Criteria:
- Diagnosis of EBV+ disease.
- Eastern Cooperative Oncology Group performance status ≤ 3 for participants aged ≥ 16 years; Lansky score ≥ 20 for participants from ≥ 1 year to < 16 years.
- Adequate organ function test results, unless organ dysfunction is considered to be due to the underlying EBV-associated disease by the investigator.
Cohort-specific Inclusion Criteria:
-
For participants with CNS PTLD:
- R/R or newly diagnosed EBV+ CNS PTLD for whom the standard. first-line therapy is inappropriate, as determined by the investigator. The CNS PTLD is histologically confirmed by at least biopsy-proven EBV+ CNS PTLD or positive CSF cytology with or without radiographically measurable intracranial disease with EBV detected in CSF.
- Participants with R/R disease must have had at least one prior line of systemic therapy and one of the following: radiographic disease progression per Lugano Classification during or after treatment or failure to achieve a CR or PR (defined by Lugano radiographic criteria) after standard first-line therapy.
- Participant may have systemic and CNS disease or CNS disease only.
Exclusion Criteria:
-
Currently active Burkitt, T-cell, natural killer/T-cell lymphoma/LPD, Hodgkin, plasmablastic, transformed lymphoma, active hemophagocytic lymphohistiocytosis, or other malignancies requiring systemic therapy.
-
Serious known active infections, defined as ongoing uncontrolled adenovirus infection or infections requiring systemic therapy at the time of enrollment, or known history of human immunodeficiency virus (HIV) infection.
-
Suspected or confirmed Grade ≥ 2 acute graft-versus-host disease (GvHD) per the Center for International Blood and Marrow Transplant Research (CIBMTR) consensus grading system or extensive chronic GvHD per National Institutes of Health (NIH) consensus criteria at the time of the enrollment.
-
Need for vasopressor or ventilatory support at the time of enrollment.
-
Prior therapy (in order of increasing washout period) prior to enrollment as follows:
- Within 4 weeks or 5 half-lives (whichever is shorter) for any investigational product and/ or any chemotherapy (systemic or intrathecal), targeted small molecule therapy, or antibody/biologic therapy. Note: prior anti-CD20 antibody use is permitted within the washout period if a subsequent disease response assessment indicates disease progression.
- Within 8 weeks: prior tabelecleucel (> 8 weeks prior to enrollment) is permitted if response was obtained or if usual protocol-directed therapeutic options were not exhausted, for cellular therapies (chimeric antigen receptor therapies directed at T-cells or T-cell subsets, donor lymphocyte infusion, other CTLs or virus-specific T-cells); and/or therapies which could impact tabelecleucel function (anti-thymocyte globulin, alemtuzumab).
- Any prior treatment with EBV-CTLs with the exception of tabelecleucel as above
-
Women who are breastfeeding or pregnant.
-
Unwilling to comply with protocol specified contraceptive/reproductive restrictions from enrollment through 90 days after the last treatment.
-
Inability or unwillingness to comply with all study procedures.
-
Ongoing need for daily steroids of > 0.5 mg/kg prednisone or glucocorticoid equivalent, ongoing methotrexate, or extracorporeal photopheresis (for participants with CNS disease, protocol-specified dexamethasone is permitted and concludes by the time of enrollment).
-
Any conditions that may put the study outcomes at undue risk (life expectancy < 60 days or any life-threatening illness, medical condition, or organ system dysfunction).
공부 계획
연구는 어떻게 설계됩니까?
디자인 세부사항
- 주 목적: 치료
- 할당: 무작위화되지 않음
- 중재 모델: 병렬 할당
- 마스킹: 없음(오픈 라벨)
무기와 개입
참가자 그룹 / 팔 |
개입 / 치료 |
|---|---|
|
실험적: EBV+ PID LPD
Participants with R/R or newly diagnosed EBV+ PID LPD for whom standard first-line therapy is inappropriate, will receive IV tabelecleucel. |
Tabelecleucel is being investigated as an off-the-shelf, allogeneic T-cell immunotherapy for the treatment of EBV+ malignancies and diseases.
다른 이름들:
|
|
실험적: EBV+ AID LPD
Participants with R/R or newly diagnosed EBV+ AID LPD for whom standard first-line therapy is inappropriate, will receive IV tabelecleucel. Cohort closed for enrollment after completion of stage1 |
Tabelecleucel is being investigated as an off-the-shelf, allogeneic T-cell immunotherapy for the treatment of EBV+ malignancies and diseases.
다른 이름들:
|
|
실험적: EBV+ CNS PTLD
Participants with R/R or newly diagnosed EBV+ CNS PTLD for whom standard first-line therapy is inappropriate, will receive IV tabelecleucel. |
Tabelecleucel is being investigated as an off-the-shelf, allogeneic T-cell immunotherapy for the treatment of EBV+ malignancies and diseases.
다른 이름들:
|
|
실험적: EBV+ 1L PTLD (inappropriate for first-line therapy or CD20-negative)
Participants with EBV+ PTLD for whom standard first-line therapy (rituximab or chemotherapy) is inappropriate, including CD20-negative disease, will receive IV tabelecleucel. |
Tabelecleucel is being investigated as an off-the-shelf, allogeneic T-cell immunotherapy for the treatment of EBV+ malignancies and diseases.
다른 이름들:
|
|
실험적: EBV+ sarcoma, including LMS, or smooth muscle tumors
Participants with newly diagnosed EBV+ sarcoma for whom the standard first-line therapy is inappropriate, including LMS or smooth muscle tumor, will receive IV tabelecleucel. |
Tabelecleucel is being investigated as an off-the-shelf, allogeneic T-cell immunotherapy for the treatment of EBV+ malignancies and diseases.
다른 이름들:
|
연구는 무엇을 측정합니까?
주요 결과 측정
결과 측정 |
기간 |
|---|---|
|
객관적 반응률(ORR)
기간: 최대 2년
|
최대 2년
|
2차 결과 측정
결과 측정 |
기간 |
|---|---|
|
전체 생존(OS)
기간: 최대 2년
|
최대 2년
|
|
무진행생존기간(PFS)
기간: 최대 2년
|
최대 2년
|
|
응답 기간(DOR)
기간: 최대 2년
|
최대 2년
|
|
EBV+ PID LPD 코호트의 경우: 기저 질환에 대한 최종 요법(즉, 동종이계 HCT)에 도달한 참가자 수
기간: 최대 2년
|
최대 2년
|
|
EBV+ PID LPD 코호트: 최종 치료까지의 시간
기간: 최대 2년
|
최대 2년
|
|
LMS 또는 평활근 종양을 포함한 EBV+ 육종 코호트의 경우 : 임상 적 이익률
기간: 최대 2 년
|
최대 2 년
|
|
LMS 또는 평활근 종양을 포함한 EBV+ 육종 코호트의 경우, 고형 종양 (IRECIST) 기준의 면역 반응 평가 기준에 의한 ORR : ORR
기간: 최대 2 년
|
최대 2 년
|
|
부작용(AE)을 경험한 참가자 수
기간: 최대 2년
|
최대 2년
|
공동 작업자 및 조사자
연구 기록 날짜
연구 주요 날짜
연구 시작 (실제)
기본 완료 (추정된)
연구 완료 (추정된)
연구 등록 날짜
최초 제출
QC 기준을 충족하는 최초 제출
처음 게시됨 (실제)
연구 기록 업데이트
마지막 업데이트 게시됨 (실제)
QC 기준을 충족하는 마지막 업데이트 제출
마지막으로 확인됨
추가 정보
이 연구와 관련된 용어
키워드
추가 관련 MeSH 약관
기타 연구 ID 번호
- ATA129-EBV-205/F60085DL205
- 2024-516623-14-00 (씨티스)
개별 참가자 데이터(IPD) 계획
개별 참가자 데이터(IPD)를 공유할 계획입니까?
약물 및 장치 정보, 연구 문서
미국 FDA 규제 의약품 연구
미국 FDA 규제 기기 제품 연구
이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .